Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Can Sustained Product Momentum Drive BDX Stock Before Q2 Earnings?

AI-generated analysis

πŸ“… Becton, Dickinson and Company (BDX) is scheduled to report its second-quarter fiscal 2026 results on May 7 before the market opens.

πŸ’° In the most recently reported quarter, BDX adjusted EPS of $2.91 exceeded the Zacks Consensus Estimate by 3.2%.

πŸ“‰ Over the trailing four quarters, the company has consistently outperformed earnings estimates with an average surprise of 3.5%.

⚠️ BD Life Sciences is expected to face continued pressure in Q2 due to U.S. point-of-care headwinds and unfavorable market dynamics in China.

πŸ”¬ Biosciences within the Life Sciences segment encountered lower research funding and tough prior-year comparisons affecting licensing revenues.

πŸ”„ The completion of the spin-off and combination with Waters Corporation has influenced reported performance for BD Life Sciences.

πŸ’‘ BD Interventional is expected to maintain momentum with mid-single-digit growth driven by strong performance in Urology & Critical Care.

🩺 Growth in the Interventional segment was supported by double-digit expansion in the PureWick franchise and continued strength in Peripheral Intervention.

πŸš€ Product innovations, including the expansion of the Surgiphor wound irrigation portfolio and CE marking for the Revello vascular covered stent, are contributing to revenue growth.

πŸ’Š BD Medical is expected to carry forward solid Q1 performance driven by double-digit expansion in biologic drug delivery within BioPharma Systems.

πŸ”Œ Connected Care segment momentum is being driven by growth in pharmacy automation and advanced patient monitoring platforms like HemoSphere Alta.

🩸 Specimen Management growth is supported by ongoing demand for the BD Vacutainer portfolio to improve workflow efficiency.

πŸ“‰ The Zacks Consensus Estimate for Q2 fiscal 2026 total revenue is pegged at $4.67 billion, implying an 11.5% decline year-over-year.

πŸ’Έ EPS consensus estimates are currently set at $2.77, indicating a projected 17.3% decrease from the prior year.

πŸ“‰ Over the past three months, BDX shares have declined by 27.8%, significantly underperforming the Medical - Dental Supplies sector and the S&P 500.

πŸ₯ Key peers including The Cooper Companies, Henry Schein, and McKesson Corporation have outperformed BDX over the same timeframe.

⭐ BDX currently carries a Zacks Rank of #3 (Hold) and has an Earnings ESP of -0.24%, which may indicate a lower chance of beating estimates compared to higher-ranked stocks.

Bullish Signals
  • BDX delivered adjusted earnings per share of $2.91 in the last reported quarter, surpassing analyst estimates by 3.2%.
  • Over a trailing four-quarter period, the company has outperformed consensus estimates on all occasions with an average earnings surprise of 3.5%.
  • BD Interventional is expected to maintain momentum driven by mid-single-digit growth in the first quarter, including high single-digit expansion in Urology & Critical Care.
  • The PureWick franchise within BD Interventional achieved double-digit growth, supported by continued strength in Peripheral Intervention and oncology portfolios.
  • The Surgery business saw robust growth aided by strong performance in advanced tissue regeneration and infection prevention products.
  • Product innovations such as the expansion of the Surgiphor wound irrigation portfolio and CE marking for the Revello vascular covered stent in Europe are expected to drive early adoption and growth.
  • BD Interventional revenues are projected to increase to $1.36 billion, representing a 7.4% uptick from the year-ago quarter's reported figure.
  • BD Medical demonstrated broad-based growth across key platforms, including double-digit expansion in biologic drug delivery and high single-digit growth in advanced patient monitoring.
Risk Factors
  • BDX's stock has lost 27.8% over the past three months, significantly underperforming peers like McKesson Corporation (down 14.9%), Henry Schein (down 3.1%), and The Cooper Companies (down 21.5%).
  • The company carries a Zacks Rank #3 (Hold), which is neutral or potentially bearish compared to the Strong Buy or Buy ratings that indicate higher chances of beating earnings estimates.
  • Earnings ESP stands at -0.24%, indicating an expectation for the stock to underperform its historical earnings surprises prior to this quarter's report.
  • BD Life Sciences segment revenues are expected to remain under pressure due to headwinds in Diagnostic Solutions (U.S. point-of-care issues, unfavorable China market dynamics) and Biosciences (lower research funding, tough licensing comparisons).
  • Consensus estimates for second-quarter fiscal 2026 show a significant decline of 11.5% in total revenues and a 17.3% decrease in EPS compared to the prior-year quarter.
  • U.S. point-of-care headwinds and unfavorable market dynamics in China continue to weigh on the Diagnostic Solutions business within BD Life Sciences.
Full Analysis
Becton Dickinson and Company (BDX) is set to report its second-quarter fiscal 2026 earnings on May 7, before the market opens. The company previously beat analyst estimates, with adjusted EPS of $2.91 surpassing consensus by 3.2% in the last quarter and consistently outperforming expectations over the trailing four months. Analysts expect segment performance to be mixed ahead of the report. BD Life Sciences is anticipated to face continued pressure due to headwinds in Diagnostic Solutions and Biosciences, which recently completed a spin-off and combination with Waters Corporation; revenue estimates for this segment are set at $372 million. Conversely, BD Interventional is expected to maintain momentum driven by strong performance in key growth platforms like PureWick, Peripheral Intervention, and Surgery, with a consensus revenue estimate of $1.36 billion representing an estimated 7.4% increase from the prior period. The wider market context shows BDX stock has lost 27.8% over the past three months, significantly underperforming both its peers in the medical supplies sector and the broader S&P 500. Consensus estimates for total revenue and EPS for the upcoming quarter are projected at $4.67 billion and $2.77 respectively, though these figures imply declines from the prior-year quarter of 11.5% and 17.3%. The Zacks Rank is currently #3, and the Earnings ESP stands at -0.24%, suggesting a lower probability of beating estimates compared to stocks with positive signals.